
Release date: 2026-01-23 16:51:28 Article From: Lucius Laos Recommended: 10
This drug is a prescription medicine. Its use must strictly follow the doctor’s instructions, and it shall not be purchased or dosed without authorization.
The price of Lorlatinib varies depending on specifications, regions and purchase channels. In the domestic market, the price per box usually ranges from 20,000 to 40,000 RMB. The specific price shall be subject to the actual selling price of hospitals or licensed pharmacies.
The specifications of the drug (e.g., 30 tablets or 60 tablets per box) directly affect the price. The unit price of large-packaging products may be relatively lower.
Regional policy differences are significant. For example, the price in Hong Kong may be slightly lower than that in mainland China, while prices in European and American countries are generally higher due to exchange rates and high circulation costs.
Medical insurance reimbursement policies and charitable drug donation programs can reduce the financial burden on patients. This drug has been included in the medical insurance catalog in some cities, with a reimbursement rate of approximately 50%–70%.
The drug shall be purchased with a doctor’s prescription. It is recommended to obtain it through formal hospitals or authorized pharmacies and avoid channels of unknown origin.
During the medication period, it is necessary to review liver function, blood routine and other indicators regularly. Doctors will adjust the treatment plan based on the therapeutic effect and side effects.
If severe adverse reactions occur (such as dyspnea or arrhythmia), the medication must be stopped immediately and medical advice shall be sought without delay.
After being diagnosed with lung cancer, patients are advised to first ask an oncologist to evaluate the results of genetic testing to confirm whether they meet the indications for Lorlatinib (e.g., ALK or ROS1 gene mutations).
Patients with financial difficulties can consult their attending physicians or social workers to apply for pharmaceutical company assistance programs or foundation subsidies.
Before taking the medicine, patients must fully communicate their past medical history and medication history with doctors to ensure the safety and effectiveness of the treatment.
On November 21, 2025, the U.S. Food and Drug Administration (FDA) approved the regimen of pembrolizu···【more】
Recommended:672025-17-12
Lung cancer is the most rapidly increasing malignant tumor with the fastest increasing morbidity and···【more】
Recommended:3652024-09-07
On December 12, 2025, the U.S. Food and Drug Administration (FDA) approved niraparib in combination ···【more】
Recommended:602025-15-12
The U.S. Food and Drug Administration (FDA) announced today that it has approved Omisirge (omidubice···【more】
Recommended:792025-10-12
On December 4, 2025, the U.S. Food and Drug Administration (FDA) approved lisocabtagene maraleucel (···【more】
Recommended:742025-08-12
On December 3, 2025, the U.S. Food and Drug Administration (FDA) granted full approval to pirtobruti···【more】
Recommended:942025-04-12
Primary analysis data from the randomized, double-blind, placebo-controlled phase III HER2CLIMB-02 s···【more】
Recommended:892025-01-12
The Cure SMA Foundation, a global leading non-profit organization dedicated to spinal muscular atrop···【more】
Recommended:922025-27-11

Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp: